
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences has demonstrated robust growth in its revenue streams, with TAVR sales increasing by 10.6% year-over-year, amounting to approximately $1.16 billion and surpassing consensus estimates. The company's TMTT segment experienced impressive growth of 48.3% year-over-year, reflecting strong adoption of its Pascal and Evoque products. Furthermore, management has expressed increased confidence in achieving its prior 2026 sales guidance of 8-10% year-over-year growth, which reinforces a positive outlook for the company's financial trajectory.
Bears say
Edwards Lifesciences has demonstrated a mixed financial performance, with adjusted operating margin falling short of consensus estimates due to elevated selling, general, and administrative expenses, ultimately leading to a notable earnings per share miss. While the company's transcatheter aortic valve replacement (TAVR) sales exceeded consensus expectations, surgical structural heart sales lagged behind, reflecting broader risks such as hospital staffing issues, competition, and potential delays in product development. The outlook is further complicated by market dynamics, including the potential for slower growth trajectories in key segments and challenges from emerging competitors, which could hinder the company's ability to maintain its position in the medical device market.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares